Straits Times Index
3,330.81 +0.80 (+0.02%) S&P 500
5,350.21 -3.82 (-0.07%) Dow
38,866.04 +58.71 (+0.15%) Nasdaq
17,173.68 -14.22 (-0.08%) Bitcoin USD
71,002.09 -597.65 (-0.83%) CMC Crypto 200
1,521.16 -3.64 (-0.24%)
AbbVie Inc. (ABBV)
| Previous close | 165.44 |
| Open | 165.49 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1100 |
| Day's range | 164.35 - 167.90 |
| 52-week range | 130.96 - 182.89 |
| Volume | |
| Avg. volume | 5,747,106 |
| Market cap | 296.039B |
| Beta (5Y monthly) | 0.58 |
| PE ratio (TTM) | 49.89 |
| EPS (TTM) | 3.36 |
| Earnings date | 25 Jul 2024 - 29 Jul 2024 |
| Forward dividend & yield | 6.20 (3.75%) |
| Ex-dividend date | 12 Apr 2024 |
| 1y target est | 183.88 |
ZacksAbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug
The late-stage study will evaluate AbbVie's (ABBV) experimental antibody to treat patients with relapsed/refractory multiple myeloma who have received at least two lines of prior therapy.
PR NewswireAbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian Cancer
AbbVie (NYSE: ABBV) announced today positive topline results from the Phase 2 PICCOLO trial evaluating investigational mirvetuximab soravtansine (ELAHERE®) monotherapy in heavily pre-treated patients with folate receptor-alpha (FRα) positive, platinum-sensitive ovarian cancer (PSOC). The study met its primary endpoint with an objective response rate (ORR) of 51.9% (95%CI 40.4 – 63.3%).
PR NewswireSkinMedica® Celebrates 25 Years of Empowering Radiant Skin
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), the makers of BOTOX® Cosmetic (onabotulinumtoxinA), is celebrating 25 years of SkinMedica®. To mark this milestone anniversary, Allē Members who purchase SkinMedica® products at a participating Allē Health Care Provider or SkinMedica.com from June 1 to June 25, 2024 can earn double points* and enter for a chance to win $5,000.**
